Study Finds Efficacy of Novel Prostate Cancer Molecular Imaging Drug

Study Finds Efficacy of Novel Prostate Cancer Molecular Imaging Drug
shutterstock_170628545A recent study titled “99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer” published in The Journal of Nuclear Medicine, has assessed the potential of a novel drug to detect and visualize early prostate cancer in soft tissue, lymph nodes and bone. The research team, lead by Shankar Vallabhajosula, PhD, Professor of Radiochemistry in Radiology at Weill Cornell Medical College, compared the pharmacokinetics, biodistribution, and tumor uptake of two Tc-99m labeled ligands, MIP-1404 and MIP-1405, in either 6 healthy controls or 6 patients demonstrating radiographic evidence of metastatic prostate cancer. After the investigational drug was injected, patients had whole body images taken at 10 minutes and at 1, 2, 4 and 24 hours after injection, along with single-photon emission computed tomography (SPECT), a tomographic imaging technique that uses gamma rays to provide true 3D information. This was the first study to use single target-specific Tc-99m based on SPECT for
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *